Hemophagocytic Lymphohistiocytosis (HLH) and Sarcoidosis: A Complex Case Study

This case study delves into a challenging scenario where a hepatologist grapples with a patient presenting HLH associated with liver injury in the context of sarcoidosis. Despite inconclusive initial investigations, further work-up reveals indications of secondary HLH/MAS. The management involves a careful balance of treatments to address both conditions, raising questions on the differentiation of hepatic sarcoidosis from HLH and the efficacy of low-dose steroids in suppressing HLH.

• HLH
• Sarcoidosis
• Liver Injury
• Hepatologist
• Differential Diagnosis

legolasm Follow

Uploaded on Sep 17, 2024 | 0 Views

Download Presentation

Please find below an Image/Link to download the presentation.

The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. Download presentation by click this link. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.

Presentation Transcript

1. Preceptorship Programme 23 to 25 May 2022 Case: Hemophagocytic Lymphohistiocytosis (HLH) associated with liver injury in Sarcoidosis hepatologist on the horns of a dilemma Dr Prajna Anirvan Department of Gastroenterology SCB Medical College, Cuttack India.

2. Background History

3. Index Presentation

4. Initial Labs and Provisional Diagnosis Parameter Value Hemoglobin (gm/dL) 11 USG abdomen Hepatomegaly (21 cm) with Grade 2 Fatty Changes, IHBR normal, no SOL, Splenomegaly, Few mildly enlarged porta hepatic nodes (13 mm), Portal vein - not dilated. MRI abdomen with MRCP Hepatomegaly, no SOL, IHBR normal Splenomegaly UGI endoscopy: Normal mucosal study till D2, no varices ESR (mm AEFH)/ CRP (mg/L) Total leukocyte Count (x10 /mm ) Platelet Count (x10 /mm ) 6 38 2.8 210 Total Bilirubin/Direct Bilirubin (mg/dL) AST (IU/L) 7.2/4.1 Etiological work up HAV/HEV IgM: non reactive HbsAg, HCV, Anti-HBc Total - negative CMV, EBV, HIV, COVID-19 RTPCR Negative Malaria/Dengue: Neg Blood, Urine Cultures : Sterile Procalcitonin: 0.2 g/L ANA- negative, AIH profile- negative Mantoux Test- Non reactive, IGRA - negative 727 ALT (IU/L) 606 ALP (IU/L) 817 Albumin/globulin (gm/dL) 3.1/3.0 INR 1.29 Creatinine (mg/dL) 0.7 ? Sarcoidosis with hepatic involvement not responding to steroids Na/K (mmol/L) 128/4.3 Fasting Blood Sugar (mg/dL) 89

5. Clinical Course and Further Work up Parameter Serum triglyceride (mg/dL) Serum ferritin ( g/L) Serum LDH (IU/L) Value Reference range 45-150 1463 Is it In view of raised CRP and normal ESR Secondary Hemophagocytic Lymphohistiocytosis(HLH)/ Macrophage Activation Syndrome(MAS)??? 13-400 >2000 200-450 1811 Serum fibrinogen (mg/dL) 110-420 73.6

6. Liver Histopathology and Bone Marrow Study

7. Management Day 7 Parameter Bilirubin (mg/dL) AST (IU/L) ALT (IU/L) ALP (IU/L) Bilirubin (mg/dL) AST (IU/L) ALT (IU/L) ALP (IU/L) Value 7.1 267 231 750 3.9 76 81 510 Parameter Bilirubin(mg/dL) Value 0.6 Day 90 AST(IU/L) 67 ALT 53 ALP 245 Day 30 USG(abdomen)- Grade II fatty liver, liver span-15 cm

8. Questions How commonly is sarcoidosis complicated by HLH/MAS? Was hepatosplenomegaly due to HLH per se or due to sarcoidosis involving the liver? How to distinguish hepatic sarcoidosis from HLH in the background of deranged LFT? Did low dose steroid (10 mg/day) which patient was taking suppress HLH from manifesting initially?